IN ACTIVE PSORIATIC ARTHRITIS

STELARA® Starts Upstream in the Inflammatory Cascade

 

DISRUPTING THE ACTIVATION OF
INFLAMMATORY CASCADE

 

ACTIVATED INFLAMMATORY
CASCADE

 
  • STELARA® is a human IgG1k monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-23 and IL-12 cytokines1,2
  • IL-23 and IL-12 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation2
  • In in vitro models, STELARA® was shown to disrupt IL-23– and IL-12–mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ12
  • By targeting the upstream regulatory cytokines IL-23 and IL-12, STELARA® was shown to disrupt the resultant inflammatory cascade2
  • The clinical significance of these characteristics is not fully known

    The only available biologic that

    targets the IL-23/12 cytokines1-7

05/20 cp-92848v1

References: 1. McInnes IB, Kavanaugh A, Gottlieb AB, et al; for the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet. 2013;382(9894):780-789. 2. STELARA® [Prescribing Information]. Horsham, PA: Janssen Pharmaceuticals, Inc.